Reading the annual reports…
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
KMDA · Nasdaq · United States · Pharmaceutical Preparations
In shortKAMADA LTD is profitable, generates cash and holds more cash than debt, with revenue growing (+12.1% last year).
Financial health
Strong
Built from five areas over the last five annual reports. Tap an area to see the figures behind it.
| Operating marginShare of each sale left after running the business, before interest and tax. | 14.5% | 65/100 |
|---|---|---|
| Net marginShare of each sale left as profit after every cost, interest and tax. | 11.2% | 65/100 |
| Return on equityProfit earned on the money shareholders put in. Above 15% is strong. | 7.6% | 38/100 |
| Return on invested capitalProfit earned on all the capital used (equity and debt). Above 10% usually means a real competitive edge. | 8.1% | 54/100 |
Weight in the score: 25%
| Current ratioShort-term assets divided by short-term debts. Below 1 can mean tight cash. | 4.07× | 100/100 |
|---|---|---|
| Debt / equityDebt compared with the shareholders' stake. Above 2 is heavily indebted. | 0.04× | 100/100 |
| Net debt / EBITDAYears of operating profit needed to repay net debt. Below 2 is comfortable. | Net cash | 100/100 |
| Interest coverageHow many times operating profit covers interest. Below 2 is risky. | 30.36× | 100/100 |
| Altman Z''Bankruptcy-risk model. Above 2.6 safe, below 1.1 distress. | 5.42 | 100/100 |
Weight in the score: 25%
| Free cash flow marginCash left from each sale after investments. The money that can pay dividends or reduce debt. | 14.1% | 77/100 |
|---|---|---|
| Free cash flow / net incomeHow much accounting profit turns into real cash. Near 1 or above is healthy. | 1.26× | 100/100 |
| Years with positive free cash flow (last 5) | 4 of 5 | 75/100 |
Weight in the score: 20%
| Profitable years (last 5) | 3 of 5 | 60/100 |
|---|---|---|
| Years of revenue decline (last 5) | 1 of 5 | 67/100 |
| Revenue growth volatility | 17.6% | 46/100 |
| Operating margin volatility | 6.3% | 52/100 |
Weight in the score: 20%
| Revenue growth, 3-year average | 11.7% | 82/100 |
|---|---|---|
| EPS growth, 3-year average | – | n/a |
Weight in the score: 10%
Fiscal year 2025 · change vs prior year
Annual figures as reported. Hover a bar or point for the exact value.
5 older years available with the 10-year history. Essential plan, from €8.25/month →
The last 5 fiscal years from the company's annual reports.
USD millions; negative values in parentheses.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | 104 | 129 | 143 | 161 | 180 |
| Cost of revenue | 73 | 83 | 87 | 91 | 104 |
| Gross profit | 30 | 47 | 55 | 70 | 76 |
| Research & development | 11 | 13 | 14 | 15 | 13 |
| Selling, general & admin | 0.3 | 1.8 | – | – | – |
| Operating income | (0.7) | 4.5 | 10 | 20 | 26 |
| Interest expense | 0.3 | 0.9 | 1.3 | 0.7 | 0.9 |
| Pre-tax income | (1.9) | (2.3) | 8.4 | 13 | 23 |
| Income tax | 0.3 | 0.1 | 0.1 | (1.1) | 3.3 |
| Net income | (2.2) | (2.3) | 8.3 | 14 | 20 |
| Diluted EPS | −$0.05 | −$0.05 | $0.15 | $0.25 | $0.35 |
| Diluted shares (millions) | 45 | 45 | 54 | 58 | 58 |
5 older years available with the 10-year history. Essential plan, from €8.25/month →
The last 8 reported quarters (10-Q and 10-K filings), in USD millions. The fourth quarter is derived from the annual report.
The last 8 quarters of KAMADA LTD are included in the Investor plan. Try free for 7 days →
5.42 Safe zone
Estimates bankruptcy risk from working capital, retained earnings, operating profit and equity. Above 2.6 is considered safe, below 1.1 signals distress.
7/9
Nine yes-or-no tests on profitability, debt, liquidity and efficiency versus the prior year. 7 to 9 is strong, 0 to 3 is weak.
All figures: SEC EDGAR. Ratios and scores are computed by Scorvest (see how it works). Information only, not investment advice. How it works
Latest annual report: Dec 31, 2025 · Data updated Mar 11, 2026